Cure My Disease

Don't miss your cure!

 Log in / Sign up

Predicting the unpredictable: new model aims to forecast brain bleeds in moyamoya

NCT ID NCT07781579

Knowledge-focused Sponsor: Beijing Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This study is developing a model to predict the risk of brain hemorrhage in people with moyamoya disease, a condition where brain arteries become blocked and fragile. The researchers will use ultra-high-field 5T MRI to see fine details of blood vessels and analyze blood and urine for metabolic markers. They will follow 500 participants for 12 months to see who experiences a new bleed, then use that data to build a risk prediction tool. The goal is to identify high-risk patients early so they can receive timely surgical treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
5T MRI and metabolomic profiling (no drug or device intervention)
What this could lead to
If successful, this could lead to a tool that predicts which moyamoya patients are at highest risk of bleeding, helping doctors decide who needs surgery sooner.
What could go wrong
This is an early-stage observational study, so the model may not be accurate enough for widespread use. It also requires advanced 5T MRI, which is not widely available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with moyamoya disease or moyamoya syndrome confirmed by digital subtraction angiography (DSA) at the Department of Neurosurgery, Beijing Hospital, who meet the eligibility criteria and provide written informed consent. Participants are classified into a hemorrhagic-type group and an ischemic-type group according to their initial clinical presentation.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Moyamoya disease or moyamoya syndrome confirmed by digital subtraction angiography (DSA). * Able to undergo a 5.0T magnetic resonance imaging (MRI) examination. Exclusion Criteria: * Claustrophobia or any other condition precluding completion of imaging acquisition. * Previous revascularization surgery in both cerebral hemispheres. * Any intracranial hemorrhage event within 1 month before enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intracranial hemorrhages are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intracerebral hemorrhage Intracranial Hemorrhages Moyamoya disease stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intracranial hemorrhages Moyamoya disease Stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.